Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2–4 (SPACE trial)

INTRODUCTION: Hereditary proximal spinal muscular atrophy (SMA) is caused by homozygous loss of function of the survival motor neuron 1 gene. The main characteristic of SMA is degeneration of alpha motor neurons in the anterior horn of the spinal cord, but recent studies in animal models and patient...

詳細記述

保存先:
書誌詳細
出版年:BMJ Open
主要な著者: Stam, Marloes, Wadman, Renske I, Wijngaarde, Camiel A, Bartels, Bart, Asselman, Fay-Lynn, Otto, Louise A M, Goedee, H Stephan, Habets, Laura E, de Groot, Janke F, Schoenmakers, Marja A G C, Cuppen, Inge, van den Berg, Leonard H, van der Pol, W Ludo
フォーマット: Artigo
言語:Inglês
出版事項: BMJ Publishing Group 2018
主題:
Neurology
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6067401/
https://ncbi.nlm.nih.gov/pubmed/30061431
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2017-019932
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料